Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors combined with bevacizumab in the treatment of advanced non-small cell lung cancer
10.6039/j.issn.1001-0408.2024.23.14
- VernacularTitle:PD-1/PD-L1抑制剂联合贝伐珠单抗治疗晚期非小细胞肺癌疗效与安全性的Meta分析
- Author:
Hongmei LUO
1
;
Jiafeng ZOU
;
Jiufeng ZHAO
;
Chengxin SUN
;
Jianwen YANG
Author Information
1. 遵义医科大学附属医院药剂科,贵州遵义 563000
- Publication Type:Journal Article
- Keywords:
non-small cell lung cancer;
PD-1/PD-L1 inhibitors;
bevacizumab;
efficacy;
safety
- From:
China Pharmacy
2024;35(23):2923-2928
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the efficacy and safety of programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors combined with bevacizumab in the treatment of advanced non-small cell lung cancer (NSCLC) based on platinum-containing dual therapy. METHODS Retrieved from CNKI,Wanfang,VIP,Web of Science,PubMed and other Chinese and English databases,cohort studies or randomized controlled trial studies on the treatment of advanced NSCLC with platinum-containing double agents in combination with PD-1/PD-L1 inhibitors and bevacizumab (trial group) versus platinum-containing double agents with or without PD-1/PD-L1 inhibitor or bevacizumab (control group) were collected from the inception to April 25,2024. After screening literature,extracting data and evaluating quality,meta-analysis and sensitivity analysis were performed by using RevMan 5.4.1 software. RESULTS A total of 15 pieces of literature were included,involving 13 clinical studies with a total of 3282 patients. Compared with the control group,partial response rate[RR=0.75,95％CI(0.68,0.82),P<0.00001],complete response rate[RR=0.47,95％CI(0.29,0.76),P=0.002],progressive disease rate[RR=1.23,95％CI(1.11,1.37),P<0.0001],objective response rate (ORR)[RR=0.72,95％CI(0.67,0.79),P<0.00001]and disease control rate (DCR)[RR=0.85,95％CI (0.77,0.95),P=0.003]were higher in the trial group. There was no statistically significant difference in the stable disease rate[RR=1.25,95％CI (0.86,1.83),P=0.25]or overall adverse drug reaction incidence rate[RR=0.95,95％CI (0.90,1.00),P=0.07]between the two groups of patients. Sensitivity analyses showed robust and reliable results for all outcome indicators. CONCLUSIONS PD-1/PD-L1 inhibitors combined with bevacizumab based on platinum-containing dual therapy in the treatment of advanced NSCLC can improve patients' clinical benefits,such as ORR and DCR,without increasing the risk of adverse drug reaction.
